| Bioactivity |
MHI-148 is a near-infrared heptamethine cyanine dye with tumor-targeting properties for cancer detection, diagnosis and treatment. MHI-148 is immediately taken up and accumulated by lysosomes and mitochondria of tumor cells, but not in lysosomes and mitochondria of normal cells[1]. |
| Invitro |
MHI-148 (10 µM, 1 h) is significantly more absorbed in HT-29 colon carcinoma cells than in normal NIH3T3 fibroblasts and has tumor imaging and targeting properties[1]. MHI-148 (0-1.5 µM, 3 days) causes only negligible toxicity in HT-29 and NIH3T3 cells[1]. |
| Name |
MHI-148 |
| CAS |
172971-76-5 |
| Formula |
C42H52BrClN2O4 |
| Molar Mass |
764.23 |
| Appearance |
Solid |
| Transport |
Room temperature in continental US; may vary elsewhere. |
| Storage |
| Powder |
-20°C |
3 years |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
| Reference |
[1]. Athira Raveendran, et al. Heptamethine Cyanine Dye MHI-148-Mediated Drug Delivery System to Enhance the Anticancer Efficiency of Paclitaxel. Int J Nanomedicine. 2021 Oct 21;16:7169-7180. |
